阿卡波糖和瑞格列奈治疗2型糖尿病的药物经济学评价

摘要

Objective To evaluate the curative effect and economical efficiency of acarbose and repaglinide in treating type 2 diabetes for providing the basis for decision makers pricing and patients'selection of drugs. Methods The study was a retrospective study. After the literature analysis,the data were collected through field research,and then the samples were divided into acarbose group and repaglinide group according to different medication. Cost effectiveness analysis(CEA)and incremental cost-effectiveness analysis were used to evaluate the pharmacoeconomics. Results Baseline information was not statistically significant between two groups(P >0.05). After treatment,the levels of FPG,2hPBG and HbA1c of patients were significantly decreased in two groups(P<0.05),and the total effective rate in repaglinide group was higher. The total cost was statistically lower in repaglinide group than in acarbose group (P<0.05). The cost-effectiveness ratio in acarbose group was significantly higher than that in repaglinide group(P<0.05). Con-clusion Acarbose and repaglinide are both effective in the improvement of FPG,2hPBG and HbA1c,and the repaglinide has better effect and costs less. In terms of the perspective of pharmacoeconomics,repaglinide is more economical in the treatment of type 2 dia-betes.%目的 评估阿卡波糖和瑞格列奈治疗2型糖尿病的疗效和经济性,为决策者定价及患者选择药物提供依据. 方法采用回顾性研究,前期文献分析后通过实地调研获取数据,根据给药不同分为阿卡波糖组和瑞格列奈组,并采用成本-效果分析方法(CEA)和增量成本-效果分析对其进行药物经济学评价. 结果 两组患者的基线信息差异没有统计学意义(P>0.05);用药治疗前后患者FPG、2hPBG及HbA1c数值存在明显差异(P<0.05),瑞格列奈组用药医治的有效率较高;两组用药总成本存在明显差异(P<0.05),瑞格列奈组成本较低;阿卡波糖组用药的成本-效果比(C/E)明显高于瑞格列奈组(P<0.05). 结论 阿卡波糖和瑞格列奈在改善FPG、2hPBG及HbA1c上都有效,但瑞格列奈疗效较好一些,花费的成本也较少,因此从药物经济学角度,瑞格列奈在治疗2型糖尿病同样有效的前提下经济性更好.